Sleep Aids for People with Sleep Apnea: Which Ones Are Safe?

Fujita Health University

For the millions of people who have both insomnia and obstructive sleep apnea, getting a good night's sleep involves a genuine medical dilemma. They need help falling or staying asleep, but the medications that could help carry a worry: will they relax the airway muscles enough to make the breathing problem worse?

It is a common clinical scenario. Obstructive sleep apnea (OSA) - characterized by repeated airway collapse during sleep, causing oxygen drops and frequent awakenings - often coexists with insomnia. The combination, known as COMISA (comorbid insomnia and sleep apnea), affects a substantial portion of sleep apnea patients and complicates treatment decisions.

A team led by Professor Taro Kishi at Fujita Health University in Japan has now produced the first network meta-analysis comparing multiple sleep medications across both sleep quality and respiratory safety in adults with OSA. The findings, published in Psychiatry and Clinical Neurosciences, offer the most comprehensive comparison to date.

32 trials, 12 drugs, 17 outcomes

The researchers analyzed 32 randomized controlled trials covering 12 hypnotic medications: brotizolam, daridorexant, eszopiclone, flurazepam, lemborexant, nitrazepam, ramelteon, temazepam, triazolam, zaleplon, zolpidem, and zopiclone, plus placebo. They assessed 17 distinct outcomes organized into five categories: sleep architecture, respiratory function, treatment acceptability, treatment tolerability, and other safety outcomes.

The network meta-analysis design allows indirect comparisons between drugs that were never tested head-to-head in the same trial, providing a broader picture than any single study could.

The breathing question, largely answered

The central finding is reassuring: the study did not find broad evidence that hypnotics uniformly worsen respiratory outcomes in OSA patients. The apnea-hypopnea index - the key metric measuring how often breathing is disrupted per hour of sleep - did not significantly differ from placebo for most of the analyzed drugs.

There was one clear exception. Temazepam, a benzodiazepine, was found to decrease arterial oxygen saturation during sleep. For patients with OSA, where oxygen levels already dip repeatedly throughout the night, further reductions in oxygen saturation carry real clinical risk - including cardiovascular strain and cognitive impairment.

Different drugs for different sleep problems

The hypnotics showed varied effectiveness depending on the type of insomnia symptom. Some patients struggle primarily with falling asleep, others with waking in the middle of the night, and others with waking too early. Professor Kitajima, a co-author, emphasized that suggesting appropriate medication based on the specific insomnia symptom can aid in alleviating the problem effectively.

This is a practical insight for clinicians. Rather than treating insomnia as a monolithic condition, the data support matching the medication to the patient's specific complaint - something that clinical guidelines have recommended in principle but that has lacked comparative evidence in the OSA population specifically.

Sensitivity analysis and CPAP users

An important methodological note: the included trials enrolled both patients using continuous positive airway pressure (CPAP) therapy and those not using it. Because CPAP itself affects respiratory parameters, the researchers conducted sensitivity analyses excluding CPAP users and titration studies. The team emphasized that their findings focused on these sensitivity results for respiratory outcomes.

This distinction matters. CPAP keeps the airway open mechanically, potentially masking any respiratory worsening caused by a hypnotic. The sensitivity analysis provides a cleaner picture of how the drugs affect breathing in the absence of this airway support.

The boundaries of this evidence

Network meta-analyses are powerful tools, but they carry inherent limitations. The indirect comparisons depend on the assumption that the trial populations are similar enough to be validly compared, which may not always hold true across 32 studies conducted in different countries and clinical settings.

The individual trials varied in size, design, and patient selection criteria. Some drugs had substantially more evidence behind them than others, meaning the confidence in the findings differs across medications. For drugs with limited trial data, the results should be interpreted cautiously.

The analysis focused on polysomnographic (sleep study) outcomes - objective measurements of sleep and breathing. It did not comprehensively assess subjective outcomes like how rested patients felt, their next-day functioning, or long-term adherence to medication. Clinical trials that verify effectiveness based on patients' specific insomnia symptoms are still needed.

Professor Iwata, a co-author, noted that this is the first network meta-analysis to comprehensively compare multiple hypnotics across both sleep architecture and respiratory parameters in adults with OSA, but acknowledged that future research is needed to formally synthesize subjective outcomes.

A clearer map, not a final answer

For clinicians managing patients with both insomnia and OSA, the study provides the most comprehensive comparative evidence available. The broad finding - that most hypnotics do not uniformly worsen respiratory parameters - may provide some reassurance, though the temazepam finding reinforces caution with benzodiazepines in this population.

The emphasis on individualizing treatment based on specific insomnia symptoms, while weighing potential benefits and risks and monitoring respiratory status, reflects current best practice - now supported by more systematic evidence than was previously available.